Background
Methods
Search strategy and selection criteria
Methods of analysis/synthesis
Results
Biomarker | Total studies |
---|---|
C reactive protein | 20 |
Interleukin 6 | 10 |
Interleukin 8 | 10 |
Procalcitonin | 8 |
Tumor necrosis factor α | 2 |
Interleukin 10 | 1 |
Monocyte chemoattractant protein-1 | 1 |
Erythrocyte sedimentation rate | 1 |
Adenosine deaminase | 1 |
Serum Amyloid A Protein | 1 |
Interleukin 1 | 1 |
Interleukin 5 | 1 |
Interleukin 12 | 1 |
Interleukin 2 - receptor | 1 |
Citation | Underlying conditions | Underlying conditions | Markers studied | Number of patients | Number of episodes | Endpoints studied | Comments on endpoints |
---|---|---|---|---|---|---|---|
Ammann 2003 | Pre-B-cell ALL = 94, Other diagnosis = 191 | CRP | 111 | 285 | Significant bacterial infection | Defined as death from bacterial infection, a positive culture of normally sterile body fluids, radiologically proven pneumonia, clinically unequivocal diagnosis of a bacterial infection, or a serum CRP above 150 mg/L as an indirect sign suggesting severe bacterial infection | |
Barnes 2002 | No data given | PCT | 37 | 39 | Length of stay | Stay of < 5d or ≥5d | |
de Bont 1999 | ALL = 8, AML = 20, CML = 2, Lymphoma = 16, Solid tumor = 7 | CRP, IL6, IL8 | 19 | 72 | Bacteremia | ||
Diepold 2008 | ALL = 21, AML = 1, JMML = 1, Relapsed AML after SCT = 1, Solid tumor = 39, Hematological disorder after SCT = 4, Hematological disorder without SCT = 1 | CRP, IL6, IL8 | 69 | 123 | Bacteremia Fever lasting ≥5d but culture -ve | ||
Dylewska 2005 a and b | No data given | CRP, PCT | 66 | 108 | Bacteremia Clinically defined infections (UTI, neurological, GI or respiratory) Microbiologically defined other infection | FUO was the default category | |
El-Maghraby 2007 | ALL = 37, AML = 39, Lymphoma = 39 | CRP, IL8, MCP | 76 | 85 | Bacteremia or clinically documented infection | ||
Hatzistilianou 2007 | All patients had ALL | CRP, PCT | 29 | 94 | Microbiological or clinically documented infection (excludes viral) | ||
Heney 1992 | ALL = 17, AML = 10, Lymphoma = 2, Solid tumor = 18 | CRP, IL6 | 33 | 47 | Bacteremia | ||
Hitoglou-Hatzi 2005 | All patients had ALL | CRP, PCT, tADA | 67 | Not stated | Significant bacterial infection | ||
Hodge 2006 | No overall data given | IL8, IL5 | 31 | 31 | Positive blood culture | ||
Katz 1992 | Haematological malignancy = 82, Solid tumor = 40 | CRP | 74 | 122 | Clinically or bacteriologically documented infection Septicemia (+ve blood cultures and unwell clinical appearance) | ||
Kitanovski 2006 | Hematological malignancy = 50, Solid tumor = 18 | CRP, PCT, IL6 | 32 | 68 | Bacteremia and clinical sepsis Clinically or microbiologically documented local infection | ||
Lehrnbecher 1999 | ALL = 17, AML = 7, Lymphoma = 5, Solid tumor = 27 | CRP, PCT, IL6 | 56 | 121 | Clinically documented infection Fungal infection Bacteremia (gram-type) | FUO was the default category | |
Lehrnbecher 2004 | ALL = 48, AML = 15, Lymphoma = 16, Histiocytosis = 1, Solid tumor = 66 | IL6, IL8 | 146 | 311 | Significant bacterial infection | Defined as bacteremia, localised infection or pneumonia | |
Riikonen 1992 | No data given | IL6, IL1, TNF, SAA | 46 | 105 | Bacteremia suspected sepsis Focal infection | "No infection" was the default category | |
Riikonen 1993 | ALL = 20, AML = 24, Solid tumor = 47 | CRP | 46 | 91 | Bacteremia suspected sepsis Focal infection | "No infection" was the default category | |
Santolaya 1994 | Leukemia = 47, Lymphoma = 17, Solid tumor = 11 | CRP | 75 | 85 | Documented bacterial infection Probable bacterial infection Viral infection | Documented bacterial infection defined as bacteremia (two sets positive for commensals) or sterile site infection; Probable bacterial infection defined as cultures negative but severe medical course, for example, purulent gingivostomatitis, CXR+; FUO was the default category | |
Santolaya 2001 | ALL = 40%, AML = 8%, Relapsed leukemia = 14%, Lymphoma = 6%, Sarcoma = 17%, Other solid tumor = 15% | CRP | 257 | 447 | Invasive bacterial infection | Defined as positive blood cultures - 2 for CoNS, positive bacterial culture from usually sterile site, or sepsis syndrome and/or focal organ involvement and haemodynamic instability and severe malaise | |
Santolaya 2002 | ALL = 92, AML = 14, Lymphoma = 10, Solid tumor = 54 | CRP | 170 | 263 | Invasive bacterial infection | Defined as positive blood cultures - 2 for CoNS, positive bacterial culture from usually sterile site, or sepsis syndrome and/or focal organ involvement and haemodynamic instability and severe malaise | |
Santolaya 2007 | No overall data given | CRP | 219 | 373 | Death | ||
Santolaya 2008 | No overall data given on diagnoses. | CRP, PCT, IL8 | 278 | 566 | Severe sepsis | Defined as sepsis + respiratory or cardiac compromise, or + 2 other-organ compromise) not apparent during the first 24 h of admission | |
Secmeer 2007 | ALL and AML = 9, Lymphoma = 14, Sarcoma = 7, Histiocytosis = 1, Other solid tumor = 18 | CRP, PCR, ESR | 49 | 60 | Bacteremia Documented bacterial infection (microbiologically or clinically) Duration of fever | ||
Soker 2001 | ALL = 17, AML = 4, Lymphoma = 2 | IL6, IL8, IL2R, IL1, TNF-alpha | 23 | 48 | Bacteremia | ||
Spasova 2005 | ALL = 23, AML = 1, Lymphoma = 6, Solid tumor = 11 | CRP, IL6, IL8, IL10 | 24 | 41 | Bacteremia Microbiologically or clinically proven local infections without bacteremia | ||
Stryjewski 2005 | ALL = 35, AML = 2, Sarcoma = 8, Other solid tumor = 11 | PCT, IL6, IL8 | 56 | Not stated | Sepsis Septic shock | Sepsis (positive culture - two consecutive +ve if CoNS, fever, tachycardia, or tachypnoea); septic shock defined as sepsis plus need for inotropes/vasopressors |
Quality assessment
Data handling and analysis
Diagnostic test performance
Marker | Outcome | Cut-off | Sensitivity (95% CI) | Specificity (95% CI) |
---|---|---|---|---|
CRP (7 studies, 731 episodes) | Documented infection | > 50 mg/dl | 0.65 (0.41 to 0.84) | 0.73 (0.63 to 0.82) |
PCT (3 studies, 216 episodes) | Documented infection | > 0.2 mg/ml | 0.96 (0.05 to 0.99) | 0.85 (0.53 to 0.97) |
IL6 (3 studies, 457 episodes) | Documented infection | > 235 pg/ml | 0.68 (0.15 to 0.96) | 0.94 (0.84 to 0.98) |
IL6 (2 studies, 166 episodes) | Gram negative bacteremia | > 1,000 pg/ml | 0.78 (0.57 to 0.91) | 0.96 (0.92 to 0.99) |
Citation | Marker and Cutpoint | Outcome | Sensitivity (95% CI) | Specificity 95% CI) |
---|---|---|---|---|
Santolaya 2008 | IL8 200 | Sepsis | 0.49 (0.4 to 0.58) | 0.71 (0.67 to 0.75) |
Diepold 2008 | IL8 30 | Prolonged illness | 0.87 (0.78 to 0.93) | 0.61 (0.42 to 0.76) |
Diepold 2008 | IL8 90 | Bacterial infection | 0.64 (0.39 to 0.84) | 0.62 (0.52 to 0.71) |
El-Maghraby 2007 | IL8 62 | Documented infection | 0.71 (0.59 to 0.81) | 0.77 (0.58 to 0.89) |
Lehrnbecher 2004 | IL8 320 | Documented infection | 0.56 (0.46 to 0.65) | 0.79 (0.73 to 0.84) |
Lehrnbecher 2004 | IL8 500 | Documented infection | 0.44 (0.35 to 0.54) | 0.89 (0.84 to 0.93) |
El-Maghraby 2007 | MCP 350 | Documented infection | 0.64 (0.52 to 0.75) | 0.92 (0.76 to 0.98) |
Hitoglou-Hatzi 2005 | tADA 35 U/l | Significant bacterial infection | 1.0 (0.88 to 1.0) | 1.0 (0.91 to 1.0) |
Riikonen 1992 | TNF 40 | Bacteremia or focal infection | 1.0 (0.88 to 1.0) | 0.07 (0.03 to 0.15) |
Hodge 2006 | IL5 17 | Positive blood culture | 0.5 (0.22 to 0.79) | Could not calculate |
Hodge 2006 | IL5 and 8 combined > 17 and > 220 | Positive blood culture | 1.0 (0.68 to 1.0) | 0.87 (0.68 to 0.96) |
Soker 2001 | IL-2R | Bacteremia | Median (range) 5,230 U/mL (1,120 to 7,600) | 1,190 (724 to 5,400) |
Soker 2001 | TNF-alpha | Bacteremia | 8.4 (4.0 to 68.2) | 7.8 (3.0 to 37.2) |
Secmeer 2007 | ESR | Bacteremia | "not statistically significantly different between patients with and without documented infection" |